tradingkey.logo

Benitec Biopharma Inc <BNTC.OQ> expected to post a loss of 35 cents a share - Earnings Preview

ReutersMay 9, 2025 2:36 PM
  • Benitec Biopharma Inc BNTC.OQ BNTC.O is expected to show no change in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Benitec Biopharma Inc is for a loss of 35 cents per share.

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Benitec Biopharma Inc is $28.00​, above​ its last closing price of $13.74. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.27

-0.77

-0.33

Beat

57.1

Sep. 30 2024

-0.50

-0.55

-0.48

Beat

12.7

Jun. 30 2024

-0.53

-0.49

-1.32

Missed

-170.4​

Mar. 31 2024

-0.78

-0.78

-1.64

Missed

-110

​​Dec. 31 2023

-0.39

-0.39

-2.64

Missed

-576.9

Sep. 30 2023

-0.51

-0.51

-2.76

Missed

-441.2​

Jun. 30 2023

-3.23

-2.83

Beat

12.3

Mar. 31 2023

-3.40

-3.40

-2.72

Beat

20

This summary was machine generated May 9 at 14:36 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI